Abstract
The natural history of the development of epithelial ovarian cancer remains obscure and no effective screening test exists. In several human malignancies progression from benign to invasive tumour occurs, but this sequence has not been established for epithelial ovarian cancer. We have reviewed epidemiological, histopathological and molecular studies of benign epithelial ovarian tumours to assess the evidence for and against such a progression in ovarian cancer. These data suggest that a diagnosis of a benign ovarian cyst or tumour is associated with an increased risk of ovarian cancer later in life. Current evidence also suggests that benign serous tumours can progress to low-grade serous cancer and that benign mucinous tumours can progress to mucinous cancer. The more common high-grade serous ovarian cancers are likely to arise de novo.
Similar content being viewed by others
References
Purdie D, Webb PM, Siskind V, Bain C, Green A (2003) The different etiologies of mucinous and non-mucinous epithelial ovarian cancers. Gynecol Oncol 88(1 Pt 2):s145–s148
Risch H, Marrett L, Jain M, Howe G (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144(4):363–372
Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARCPress, Lyon
Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC, Lyon. Report No.: cancerbase No. 5
Russell P (1979) The pathological assessment of ovarian neoplasms. 1: Introduction to the common ‘epithelial’ tumours and analysis of benign ‘epithelial’ tumours. Pathology 11:5–26
Koonings PP, Campbell K, Mishell DR Jr, Grimes DA (1989) Relative frequency of primary ovarian neolpasms: a 10-year review. Obstet Gynecol 74(6):921–927
Crayford T, Campbell S, Bourne T, Rawson H, Collins W (2000) Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 355:1060–1063
Jacobs IJ, Menon U (2004) Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3(4):355–366
Russell P (1994) Surface Epithelial-Stromal tumors of the ovary. In: Kurman RJ (eds) Blaustein’s pathology of the female genital tract. Springer-Verlag, New York, pp 705–782
Ness RB (2003) Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189(1):280–294
Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23(1):41–44
Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN (2003) Pathology and classification of ovarian tumors. Cancer 97(10 Suppl):2631–2642
Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136(10):1184–1203
Hankinson S, Colditz G, Hunter D, Willett W, Stampfer M, Rosner B et al. (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76(2):284–290
Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M et al. (1997) Tubal sterilisation, Hysterectomy, and decreased risk of ovarian cancer. Int J Cancer 71:948–951
Modugno F, Ness RB, Wheeler J (2001) Reproductive risk factors for epithelial ovarian cancer according to histological type and invasiveness. Ann Epidemiol 11:568–574
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM et al. (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 83(3):575–585
Purdie D, Siskind V, Bain C, Webb PM, Green A (2001) Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 153(9):860–864
Riman T, Dickman P, Nilsson S, Correia N, Nordlinder H, Magnusson C et al. (2002) Risk factors for Invasive Epithelial Ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156(4):363–373
Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN et al. (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158(7):629–638
Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D (1987) Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J 294:1518–1520
Booth M, Beral V, Maconochie N, Carpenter L, Scott C (1992) A case-control study of benign ovarian tumours. J Epidemiol Commun Health 46:528–531
Parazzini F, Moroni S, Negri E, La Vecchia C, Mezzopane R, Crosignani PG (1996) Risk factors for seromucinous benign ovarian cysts in northern Italy. J Epidemiol Commun Health 51:449–452
Westhoff C, Britton J, Gammon M, Wright T, Kelsey J, (2000) Oral contraceptives and benign ovarian tumors. Am J Epidemiol 152:242–246
Britton J, Westoff C, Howe G, Gammon M (2000) Diet and benign ovarian tumors. Cancer Causes Control 11:389–401
Britton JA, Westhoff C, Howe GR, Gammon MD (2000) Lactose and benign ovarian tumours in a case-control study. Br J Cancer 83(11):1552–1555
Bourne T, Whitehead MI, Campbell S, Royston P, Bhan V, Collins WP (1991) Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43:92–97
Bhan V, Amso N, Whitehead M, Campbell S, Roynton P, Collins W (1989) Characteristics of persistant ovarian masses in asymptomatic women. Br J Obstet Gynaecol 96:1384–1391
Pharoah P, Ponder BA (2002) The genetics of ovarian cancer. Best Pract Res—Clin Obstet Gynaecol 16(4):449–468
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E et al. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68(3):700–710
Menkiszak J, Brzosko M, Gorski B, Flicinski J, Jakubowska A, Zebielowicz D et al. (2004) Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations. J Appl Genet 45(2):255–263
Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ et al. (2002) Infertility, fertility drugs and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 155(3):217–224
Dal Maso L, Canzonieri V, Talamini R, Franceschi S, La Vecchia C (2001) Origin of ovarian cancer from benign cysts. Eur J Can Prev 10:197–199
Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 49(13):3670–3674
Parazzini F, Moroni S, La Vecchia C, Negri E, dal Pino D, Bolis G (1997) Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 33(10):1634–1637
Borgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83(4):395–400
Swerdlow AJ, Green A (1987) Melanocytic naevi and melanoma: an epidemiological perspective. Br J Dermatol 117(2):137–146
Grulich AE, Bataille V, Swerdlow AJ, Newton-Bishop JA, Cuzick J, Hersey P et al. (1996) Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer 67(4):485–491
Webb PM, Byrne C, Schnitt SJ, Connolly JL, Jacobs T, Peiro G et al. (2002) Family history of breast cancer, age and benign breast disease. Int J Cancer 100(3):375–378
Horiuchi A, Itoh K, Shimizu M, Nakai I, Yamazaki T, Kimura K et al (2003) Towards understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol;88:309–317
Stenback F (1981) Benign, borderline and malignant serous cystadenomas of the ovary. A transmission and scanning electron microscopical study. Path Res Practice 172:58–72
Gramlich T, Austin R, Lutz M (1990) Histological sampling requirements in ovarian carcinoma: a review of 51 tumours. Gynecol Oncol 38:249–256
Puls L, Powell D, DePriest P, Gallion H, Hunter J, Kryscio R et al. (1992) Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 47(1):53–57
Scully RE (1995) Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynaecol Obstet 49(suppl):S9–S15
Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484–486
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM et al. (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496–504
Bell DA, Scully RE (1994) Early de novo ovarian carcinoma. Cancer 73(7):1859–1864
Marshall R (1993) Benign to malignant transformation in epithelial ovarian tumours—letter. Hum Pathol 24(5):562
Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC, Dubeau L (1993) Histologically benign or low-grade malignant tumours adjacent to high-grade carcinomas contain molecular characteristics of high grade carcinomas. Cancer Res 53:4138–4142
Zheng J, Benedict WF, Xu H-J, Hu S-X, Kim TM, Velicescu M et al. (1995) Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Ins 87(15):1146–1153
Kuwata T, Kitagawa M, Takemura T, Hirokawa K (1995) Proliferative activity and p 53 over-expression of ovarian epithelial tumours. Gen Diag Pathol 141(2):131–139
Wolf NG, Abdul-Karim FW, Schork NJ, Schwartz S (1996) Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential and fully malignant components. Am J Pathol 149(2):511–520
Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) k-ras mutations in mucinous ovarian tumours. Cancer 79(8):1581–1586
Mandai M, Konishi I, Kuroda H, Kaomatsu T, Yamamoto S et al. (1998) Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol 28(1):34–40
Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC (2001) k-ras mutations may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 20:244–251
Shelling AN, Cooke IE, Ganesan TS (1995) The genetic analysis of ovarian cancer. Br J Cancer 72:521–527
Wenham R, Lancaster J, Berchuck A (2002) Molecular aspects of ovarian cancer. Best Practice and Research—Clin Obstet Gynaecol 16(4):483–497
Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160(4):1223–1228
Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R et al (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202(3):336–340
Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, Berman DM et al. (2004) Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 84(6):778–784
Russell SE, McCluggage WG (2004) A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 203(2):617–619
Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5):1511–1518
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767
Acknowledgements
Dr Penelope Webb is supported by a Queensland Cancer Fund Senior Research Fellowship.
Dr Susan Jordan is supported by an Australian Postgraduate Award (University of Queensland).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jordan, S., Green, A. & Webb, P. Benign Epithelial Ovarian Tumours—cancer Precursors or Markers for Ovarian Cancer Risk?. Cancer Causes Control 17, 623–632 (2006). https://doi.org/10.1007/s10552-005-0370-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10552-005-0370-y